IL-23 antag Trials - LARVOL Sigma

252 Trials

Active Trials

12 3 »

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall

2019-002804-42: An international, multicentre, open label, interventional phase IV clinical study to investigate the efficacy and safety of tildrakizumab 100 mg in patients with moderate-to-severe chronic plaque psoriasis and its impact on their quality of life. Un estudio clínico internacional, multicéntrico, abierto, de fase IV intervencionista para investigar la eficacia y seguridad de tildrakizumab 100 mg en pacientes con psoriasis en placas crónica de moderada a grave y su influencia en la calidad de vida.

Not yet recruiting

160

Europe

Illumetri, [ILUMETRI], Solution for injection in pre-filled syringe, Illumetri

Almirall S.A., Almirall SA, Almirall S.A., Almirall SA

Moderate to severe chronic plaque psoriasis Psoriasis en placa crónica moderada a severa, Moderate to severe chronic plaque psoriasis Psoriasis en placa crónica moderada a severa, Diseases [C] - Skin and Connective Tissue Diseases [C17]

2019-003218-15: A phase IV interventional study to assess the disease-modifying effect of long-term treatment with tildrakizumab in adult patients with moderate-to-severe plaque psoriasis

Not yet recruiting

Europe

Illumetri, Solution for injection in pre-filled syringe, Illumetri

Almirall S.A., Almirall S.A.

Moderate to severe plaque psoriasis, Moderate to severe plaque psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17]

2019-004230-42: Dose reduction of IL17 and IL23 inhibitors for psoriasis Dosis reductie van IL17 en IL23 remmers voor psoriasis

Not yet recruiting

244

Europe

secukinumab, ixekizumab, brodalumab, risankizumab, tildrakizumab, guselkumab, Injection, Cosentyx, Taltz, Kyntheum, Skyrizi, Ilumetri, Tremfya

Radboudumc, ZonMw, KCE

psoriasis psoriasis, psoriasis psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17]

ChiCTR2000033239: Study for the Efficacy and Safety of Tislelizumab (Anti-PD1 Antibody) Combined With chemotherapy

Not yet recruiting

China

Tislelizumab (Anti-PD1 Antibody) Combined With chemotherapy

Zhejiang Jinhua Guangfu Tumor Hospital ; None, Beigene

Non small cell lung cancer

2019-000817-35: An open-label, randomized, Phase IV study, to assess the efficacy and safety of tildrakizumab in patients with moderate to severe chronic plaque psoriasis who are non-responders to dimethyl fumarate therapy

Not yet recruiting

250

Europe

Illumetri, Skilarence, Solution for injection in pre-filled syringe, Gastro-resistant tablet, Illumetri, Skilarence

Almirall, Almirall

Moderate to severe chronic plaque psoriasis, Moderate to severe chronic plaque psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17]

NCT05110313: Effects of Tildrakizumab on Epigenetic Age

Completed

TILDRAKIZUMAB, ILUMYA™, tildrakizumab-asmn, ATC CODE: L04AC17 (WHO)

Carlos Wambier, Sun Pharmaceutical Industries Limited, Brown University, Lifespan, Ocean State Research Institute, Inc.

Psoriasis, Aging, Epigenetic Disorder, Inflammation; Skin

05/24

BeNeBio, NCT04340076: Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

Active, not recruiting

244

Europe

Secukinumab, Cosentyx, Ixekizumab, Taltz, Brodalumab, Kyntheum, Guselkumab, Tremfya, Risankizumab, Skyrizi, Tildrakizumab, Ilumetri, Bimekizumab, Bimzelx

Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Belgium Health Care Knowledge Centre, University Hospital, Ghent

Psoriasis, Psoriasis Vulgaris

12/25

BIOLOPTIM-TIL, NCT05683015: Therapeutic Drug Monitoring of Tildrakizumab in Psoriasis Patients

Recruiting

100

Europe

Venapuncture, Patient questionnaires

University Hospital, Ghent

Psoriasis Vulgaris

12/24

12/25

NCT04541329: Predicting Inflammatory Skin Disease Response to IL-23 Blockade

Completed

Tildrakizumab

University of California, San Francisco, Sun Pharmaceutical Industries Limited

Psoriasis Vulgaris

01/23

MINIMA, NCT04271540: MIcrovascular DysfuNction in Moderate-severe Psoriasis

Active, not recruiting

Tildrakizumab, Ilumya

Marcelo F. Di Carli, MD, FACC

Psoriasis, Cardiovascular Disease

07/24

06/25

NCT05390515: Psoriatic Immune Response to Tildrakizumab

Recruiting

Tildrakizumab Prefilled Syringe

University of California, San Francisco, Sun Pharmaceutical Industries Limited

Psoriasis Vulgaris

09/25

ChiCTR2400087931: Exploration of Precision Individualized Medication Regimen for Psoriasis

Not yet recruiting

278

Secukinumab Combined with Methotrexate Group; Guselkumab Combined with Methotrexate Group; Tildrakizumab Combined with Methotrexate Group; Ustekinumab Combined with Methotrexate Group; Ixekizumab Combined with Methotrexate Group

Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, the National Key Research and Development Program of China (2023YFC2508103)

Psoriasis is a chronic inflammatory disease mediated by the immune system, influenced by both genetic and environmental factors. Clinically, it manifests as red papules or plaques with white scales. In severe cases, it can present with erythroderma or pustules, accompanied by fever and systemic pain. Besides affecting the skin, it can also cause damage to multiple organs, including nails, joints,

2020-000955-11: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)

Not yet recruiting

472

Europe

Solution for injection, ILUMETRI

Sun Pharmaceutical industries Ltd, Sun Pharmaceutical Industries Ltd, Sun Pharma Global FZE, Sun Pharmaceutical industries Ltd, Sun Pharmaceutical Industries Ltd, Sun Pharma Global FZE

Active Psoriatic Arthritis, Diseases [C] - Skin and Connective Tissue Diseases [C17]

NCT05108766: A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis

Completed

220

RoW

Tildrakizumab 100 mg, SCH 90022, MK-3222, Placebo

Shenzhen Kangzhe Pharmaceutical Co., Ltd.

Plaque Psoriasis

06/21

07/22

2020-000956-37: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Subjects with Active Psoriatic Arthritis II (INSPIRE 2)

Not yet recruiting

390

Europe

Solution for injection, ILUMETRI

Sun Pharmaceutical industries Ltd, Sun Pharmaceutical Industries Ltd, Sun Pharmaceutical industries Ltd, Sun Pharmaceutical Industries Ltd

Active Psoriatic Arthritis, Diseases [C] - Skin and Connective Tissue Diseases [C17]

NCT04314531: Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Active, not recruiting

296

Europe, Japan, US, RoW

TILD, matching placebo injections

Sun Pharmaceutical Industries Limited

Active Psoriatic Arthritis

06/25

11/25

NCT03897075: Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

Active, not recruiting

US, RoW

Tildrakizumab, Placebo

Sun Pharmaceutical Industries Limited

Chronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis

04/24

02/25

NCT04314544: Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Active, not recruiting

510

Europe, Canada, US, RoW

TILD, matching placebo injections

Sun Pharmaceutical Industries Limited

Active Psoriatic Arthritis

09/25

05/26

NCT06611163: A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

Not yet recruiting

192

Tildrakizumab 100 mg, Placebo

Sun Pharmaceutical Industries Limited

Moderate to Severe Genital Psoriasis

03/26

01/28

NCT04991116: Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

Recruiting

650

Europe, Canada, Japan, US, RoW

TILD sub-cutaneous (SC) injection

Sun Pharmaceutical Industries Limited

Psoriatic Arthritis

12/28

04/29

NCT03552276 / 2018-001060-35: Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

Completed

2/3

281

Europe, US, RoW

SUNPG18_07 I (Tildrakizumab 200 mg), SUNPG18_07 II (Tildrakizumab 100 mg)

Sun Pharmaceutical Industries Limited

Psoriatic Arthritis

09/23

NCT03997786 / 2019-003551-11: A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

Recruiting

2/3

130

Europe, US, RoW

Tildrakizumab, Placebo, Etanercept

Sun Pharmaceutical Industries Limited

Moderate-to-severe Chronic Plaque Psoriasis

07/25

12/31

ACTRN12620000984998: Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum 11 substudy 25-26: Tildrakizumab

Completed

The University of Sydney, Office for Health and Medical Research, Australian Genomic Cancer Medicine Centre (AGCMC)

Cancer, Advanced Osteosarcoma , Soft Tissue Sarcoma

2022-000706-10: Study on administration of Tildrakizumab in patients with Hidradenitis. Studie zur Anwendung von Tildrakizumab bei Patienten mit Akne.

Not yet recruiting

Europe

Solution for injection in pre-filled syringe, Ilumetri 100 mg Injektionslösung in einer Fertigspritze

University Medical Center of the Johannes Gutenberg- University Mainz, Almirall Hermal GmbH

Hidradenitis suppurativa Akne inversa, Hidradenitis Akne, Diseases [C] - Skin and Connective Tissue Diseases [C17]

ACTRN12623000211662: A Biomarker-Driven Approach to Identify Pathogenic Mechanisms and Novel Therapeutic Targets in Chronic Wounds (Pyoderma Gangrenosum) using Tildrakizumab

Completed

Liverpool Hospital, Sun Pharma

Pyoderma Gangrenosum

NCT04112810: Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease

Completed

Tildrakizumab, Iluyma

Medical College of Wisconsin

Hematologic Malignancies

06/24

2019-003485-40: ACTION: Abiraterone in Combination with Tildrakizumab

Not yet recruiting

1/2

Europe

YONSA, Ilumya, MK-3222, Tablet, Solution for infusion, YONSA, Ilumya

The Institute of Cancer Research

Metastatic castration resistant prostate cancer, Prostate cancer, Diseases [C] - Cancer [C04]

ACTIon, NCT04458311: Abiraterone Acetate in Combination With Tildrakizumab

Terminated

1/2

Europe

Abiraterone Acetate, Yonsa, Tildrakizumab

Institute of Cancer Research, United Kingdom, Sun Pharmaceutical Industries Limited

Metastatic Castration Resistant Prostate Cancer

04/23

11/23

NCT04465292: The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid

Not yet recruiting

Tildrakizumab Prefilled Syringe

Brigham and Women's Hospital, Joseph Merola

Pemphigoid, Bullous

12/22

05/23

TILDVIT-1227, NCT04971200: Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo

Completed

RoW

Tildrakizumab

Premier Specialists, Australia

Skin and Connective Tissue Diseases, Skin Diseases, Pigmentation Disorder, Hypopigmentation, Biologic, Vitiligo

11/24

SAIL, NCT04203693: Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice

Completed

N/A

331

Europe

Tildrakizumab

Almirall, S.A.

Plaque Psoriasis

04/24

NCT06488170: A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting

Recruiting

N/A

RoW

Tildrakizumab, IL-23p19 inhibitor

Almirall, S.A.

Plaque Psoriasis

01/25

ZODIPSO, NCT05938361: Efficacy of Tildrakizumab in Difficult-to-treat Areas in Psoriasis

Recruiting

N/A

120

Europe

Psoriasis clinical assessments, Quality of life evaluation, Satisfaction assessment, Pruritus evaluation

Clin4all

Psoriasis Palmaris, Psoriasis Genital, Psoriasis of Scalp, Psoriasis Plantaris, Psoriasis Nail

11/24

04/25

NCT03992729: Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab

Recruiting

N/A

200

Pregnant women exposed to tildrakizumab, Pregnant women not exposed to tildrakizumab

Sun Pharmaceutical Industries Limited

Pregnancy Related

12/25

POSITIVE, NCT04823247: Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - Study

Active, not recruiting

N/A

782

Europe

Tildrakizumab, IL-23p19 inhibitor

Almirall, S.A.

Plaque Psoriasis

01/25

NCT06030076: A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis

Recruiting

N/A

Europe

Tildrakizumab, Ilumetri®

Almirall, S.A.

Plaque Psoriasis

10/25

NCT06029257: A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)

Recruiting

N/A

110

Europe

Tildrakizumab, Ilumetri®

Almirall, S.A.

Genital Psoriasis

03/26

ACTRN12620001307998: A Prospective Photographic Analysis Of Psoriasis Severity Following Treatment With Tildrakizumab

Not yet recruiting

N/A

Samson Clinical Pty Ltd, Samson Clinical Pty Ltd

Psoriasis

ACTRN12609000233224: A Single-Dose Safety and Tolerability Placebo Controlled Study of Subcutaneous SCH 900222 in Healthy Volunteers

Recruiting

N/A

Schering-Plough, Schering-Plough

The use of SCH 900222 for autoimmune disorders.

Stelara (ustekinumab) / J&J

ACTRN12620000584932: CH-ALV-2001: A study assessing variations in how quickly STELARA is processed and cleared by the body, in healthy adult males.

Not yet recruiting

Christchurch Clinical Studies Trust, Christchurch Clinical Studies Trust

Psoriasis

2012-005809-53: What is the biologic drug concentration required to maintain stable disease activity in psoriasis?

Ongoing

Europe

adalimumab, etanercept, Ustekinumab, Solution for injection, Humira, Enbrel, Stelera

Psoriasis, Psoriasis, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]

2012-002640-25: Detecting early pre-symptomatic psoriatic arthritis in patients with skin moderate or severe psoriasis - how effective is ustekinumab (Stelara) in limiting joint disease progression and future disability?

Ongoing

Europe

Ustekinumab, Stelara, Stelara

University of Leeds/Leeds Teaching Hospitals NHS Trust, Leeds Foundation for Dermatology Research, Janssen-Cilag (Pharmaceuticals) Ltd.

Psoriatic disease (psoriasis and psoriatic arthritis).

2014-003148-11: Mechanism of action study of Ustekinumab treatment in psoriatic arthritis Studie naar het werkingsmechanisme van anti-Il17 therapie in spondyloartritis

Ongoing

Europe

ustekinumab, STELARA, STELARA

Academic Medical Center, Academic Medical Center

psoriatic arthritis artritis psoriatica

2015-000943-17: Dose decrease of biologics for psoriasis Dosis afbouwen van biologics voor psoriasis

Ongoing

120

Europe

Injection, Humira (adalimumab), Enbrel (etaneracept), Stelara (ustekinumab)

Radboudumc, Zonmw

Adult Patients diagnosed psoriasis vulgaris Volwassenen gediagnosticeerd met psoriasis vulgaris, Psoriasis Psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17]

2017-001695-26: Effectiveness and safety of biological drugs in psoriasis Efficacia e sicurezza dei farmaci biologici nella psoriasi

Not yet recruiting

154

Europe

Etanercept, Ustekinumab, ustekinumab, [xxxx], Solution for injection, STELARA - 45 MG - SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA(VETRO) O,5 ML(90MG/ML) 1 SIRINGA PRERIEMPITA DA 0.5ML, STELARA - 90 MG - SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA(VETRO) 1 ML(90MG/ML) 1 SIRINGA PRERIEMPITA DA 1 ML

ISTITUTI FISIOTERAPICI OSPITALIERI, AIFA - Italian Medicines Agency

Moderate to severe psoriasis and joint disease Psoriasi volgare da moderata a severa e artrite psoriasica, diffuse psoriasis psoriasi volgare diffusa, Diseases [C] - Skin and Connective Tissue Diseases [C17]

2017-005151-83: Treatment of Crohn's disease with Ustekinumab in clinical practice

Ongoing

100

Europe

Stelara, Concentrate for solution for infusion, Solution for injection in pre-filled syringe, STELARA

Charité Universitätsmedizin Berlin, Janssen-Cilag GmbH

Crohn's disease, Crohn's disease, Diseases [C] - Digestive System Diseases [C06]

2018-002925-47: prediction of response to therapy in inflammatory bowel disease Predicción de respuesta al tratamiento en la enfermedad inflamatoria intestinal

Not yet recruiting

180

Europe

Injection, Infusion, Adalimumab, Infliximab, Golimumab, Ustekinumab, Vedolizumab

Fundación de Investigación Biomédica del Hospital Universitario de La Princesa, Instituto de Salud Carlos III

Inflammatory bowel disease Enfermedad inflamatoria intestinal, Corhn´s disease and ulcerative colitis Enfermedad de Crohn y colitis ulcerosa, Diseases [C] - Digestive System Diseases [C06]

2018-004269-14: Use of a re-induction of Stelara (ustekinumab) through an intraveneous administration followed by a 4- or 8-weekly subcutaneous administration of Stelara to treat a loss of response to Stelara for Crohn’s disease Het gebruik van een re-inductie met Stelara® (ustekinumab) via intraveneuze toediening gevolgd door 4-of 8- wekelijkse subcutane toediening van Stelara® voor de behandeling van verlies van respons met de geregistreerde posologie van Stelara® voor de behandeling van de ziekte van Crohn. L’utilisation d’une réinduction par Stelara® (ustékinumab) par administration intraveineuse, suivie d’uneadministration sous-cutanée de Stelara® toutes les 4 ou 8 semaines pour le traitement de la perte de réponse à la posologie enregistrée de Stelara® en vue du traitement de la maladie de Crohn

Not yet recruiting

108

Europe

Solution for injection, Stelara 45 mg solution for injection

Belgian IBD research and development, Janssen Pharmaceutica NV

Crohn’s disease De ziekte van Crohn La maladie de Crohn, Chronic inflammatory bowel disease Chronische inflammatoire darmziekte la maladie inflammatoire chronique de l'intestin, Diseases [C] - Digestive System Diseases [C06]

2019-001337-13: USTekinumab in fistulising Perianal Crohn’s Disease: The USTAP CD study

Not yet recruiting

146

Europe

Concentrate for solution for infusion, Solution for injection/infusion, STELARA, STELARA 90 mg solution for injection in pre-filled syringe

GETAID, JANSSEN

patient with moderate to severe Crohn’s diseasewith at least one active perianal fistula track, Crohn's diseasefistula perianal, Diseases [C] - Digestive System Diseases [C06]

2019-002038-35: A study meausring ustekinumab concentrations through dried blood spot sampling in Crohn’s disease patients

Not yet recruiting

Europe

Solution for injection in pre-filled syringe, Stelara

UZ Leuven, UZ Leuven, Department of Gastroenterology and Hepatology, KU Leuven, Laboratorium for Therapeutic and Diagnostic Antibodies

Crohn's disease, Crohn's disease, Diseases [C] - Digestive System Diseases [C06]

ChiCTR2000034861: Efficacy and safety of Ustekinumab in the treatment of Chinese patients with Crohn's disease: a multicenter, prospective, real-world clinical study

Recruiting

127

N/A

The First Affiliated Hospital of The Fourth Military Medical University (Xijing Hospital); Xijing Hospital, IBD group

Crohn's disease

NCT04996485: Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children

Recruiting

RoW

Secukinumab Injection, Ustekinumab Injection, Dupilumab Injection, Symptomatic therapy

National Medical Research Center for Children's Health, Russian Federation

Congenital Ichthyosis

03/23

06/23

NCT02144857: Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis

Recruiting

200

Europe

etanercept, Enbrel, ustekinumab, Stelara, cyclosporine, Neoral, Secukinumab, Cosentyx, Apremilast, Otezla

University of Athens

Psoriasis

09/23

12/23

BioIBD, NCT03885713: Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease

Completed

180

Europe

Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis

12/24

USTAP, NCT04496063: USTekinumab in Fistulising Perianal Crohn's Disease

Active, not recruiting

Europe

Ustekinumab, Stelara, Placebo

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, Janssen, LP

Crohn's Disease

06/25

12/25

NCT04629196: Induction Optimization With Stelara for Crohn's Disease

Terminated

Ustekinumab, Stelara

NYU Langone Health

Crohn Disease

01/24

The relationship between drug concentration of ustekinumab and treatment efficiency in crohn's disease, ChiCTR2400084547: A multicenter study on the relationship between drug concentration of ustekinumab and treatment efficiency in crohn's disease

Completed

150

None

Jiangsu Province Hospital; Jiangsu Province Hospital, sponsored by Herui

Crohn's disease

ChiCTR2200060604: Efficacy and safety of ustekinumab intravenous maintenance versus subcutaneous maintenance in Crohn's disease: a multicenter randomized controlled clinical trial

Recruiting

ustekinumab intravenous maintenance treatment ;ustekinumab subcutaneous maintenance treatment

Xijing Hospital, Air Force Military Medical University; Xijing Hospital, Air Force Military Medical University, National Natural Science Foundation of China, Nos.81772650

Crohn's disease

SIIT-CD, NCT05861167: SIIT Based on UST CDST in Patients With CD

Recruiting

140

RoW

selective intensive induction therapy based on ustekinumab clinical decision-making tools

Sixth Affiliated Hospital, Sun Yat-sen University

Crohn Disease

06/24

NCT06520397: Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease

Recruiting

214

RoW

Ustekinumab and Upadacitinib, Ustekinumab

Sixth Affiliated Hospital, Sun Yat-sen University

Crohn Disease

12/26

07/27

ChiCTR2300070321: Comparative effectiveness of infliximab optimization vs ustekinumab for secondary loss of response to infliximab in patients with moderate-to-severe Crohn’s disease

Not yet recruiting

N/A ;N/A

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National High Level Hospital Clinical Research Funding

Crohn’s disease

NCT05270733: Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics

Recruiting

Ustekinumab, Guselkumab, Risankizumab

University Hospitals Cleveland Medical Center, LEO Foundation, Case Western Reserve University

Psoriasis

12/26

ChiCTR2200055424: Transabdominal ultrasound evaluation of transmural healing of ustekinumab in Chinese patients with active Crohn's disease: a multicenter prospective study

Recruiting

Ustekinumab therapy

Drum Tower Hospital Affiliated to Nanjing University School of Medicine; Drum Tower Hospital Affiliated to Nanjing University School of Medicine, Drum Tower Hospital Affiliated to Nanjing University School of Medicine

Crohn's disease (CD)

NCT06788340: MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease

Not yet recruiting

166

Europe

PK-model to decide when to dose Vedolizumab and Ustekinumab

Odense University Hospital

Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis

03/27

NCT05029921: A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease

Active, not recruiting

182

RoW

Ustekinumab, STELARA

Janssen Research & Development, LLC

Crohn Disease

05/25

08/25

ChiCTR2300078772: Transmural healing evaluated by endoscopic ultrasound in patients with moderate to severe active Crohn's disease in China treated with ustekinumab: a prospective single-center study

Not yet recruiting

100

None

The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, None

Crohn's disease

ChiCTR2300075237: Efficacy and safety of Ustekinumab combined with enteral nutrition in the treatment of patients with moderate to severe active Crohn's disease with small bowel stenosis: a multicenter, prospective, open-labeled, randomized controlled study

Recruiting

212

Ustekinumab; Ustekinumab combined with enteral nutrition therapy

Shanghai Tenth People's Hospital; Shanghai Tenth People's Hospital, China foundation of Crohn's disease and Colitis

Crohn's disease

NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting

150

Canada, US

Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara

Takeda

Crohn's Disease

06/27

NCT05928039: PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease

Recruiting

297

Canada

TNFa Antagonist - Infliximab, TNFa Antagonist - Adalimumab, Anti-IL12/23 or anti-IL23 - Ustekinumab, Anti-IL12/23 or anti-IL23 - Risankizumab, Anti-integrin - Vedolizumab IV, Anti-integrin - Vedolizumab IV and SC

University of Calgary, Alimentiv Inc.

Crohn Disease

07/27

12/28

SOPRANO-CD, NCT05169593: Prevention of Postoperative Endoscopic Recurrence with Endoscopy-driven Versus Systematic Biological Therapy

Recruiting

292

Europe

Biological Drug, Risankizumab, Vedolizumab, Ustekinumab, Infliximab, Adalimumab

Universitaire Ziekenhuizen KU Leuven

Crohn Disease

10/27

10/30

2020-004457-76: A Long-term Extension Study of Ustekinumab in Pediatric Participants with different medical conditions.

Ongoing

180

Europe

Ustekinumab, CNTO1275, Solution for injection, Solution for injection in pre-filled syringe, STELARA®

Janssen-Cilag International NV, Janssen Research & Development, LLC

Paediatric conditions in - Moderately to Severely Active Crohn's Disease - Moderately to Severely Active Ulcerative Colitis - Juvenile Psoriatic Arthritis, Paediatric conditions in - Crohn's Disease - Ulcerative Colitis - Juvenile Psoriatic Arthritis, Body processes [G] - Immune system processes [G12]

2017-002012-13: n.a. n.a.

Not yet recruiting

Europe

Stelara, Metotrexato, Solution for injection, STELARA - 45 MG - SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA(VETRO) O,5 ML(90MG/ML) 1 SIRINGA PRERIEMPITA DA 0.5ML, METHOTREXATE - 15 MG/2 ML SOLUZIONE INIETTABILE 4 SIRINGHE PRERIEMPITE DA 2 ML, STELARA - 90 MG - SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA(VETRO) 1 ML(90MG/ML) 1 SIRINGA PRERIEMPITA DA 1 ML

IRCCS ISTITUTO CLINICO HUMANITAS, Ministero della Salute, Janssen-Cilag S.p.A.

Moderate to severe psoriasis. Psoriasi moderata severa., n.a. n.a., Diseases [C] - Skin and Connective Tissue Diseases [C17]

2019-003151-11: Stelara for Chronic AntibioTic refractory inflammation of the pouch: A Belgian multicenter study

Not yet recruiting

Europe

Stelara, Injection, ustekinumab (Stelara)

UZ Leuven, Janssen

Chronic antibiotic refractory and relapsing pouchitis, Chronic antibiotic refractory and relapsing inflammation of the pouch, Diseases [C] - Digestive System Diseases [C06]

2020-001899-14: An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunosuppressive medication can be tapered without recurrence of symptoms

Not yet recruiting

270

Europe

Prednisolone p.o., Sulfasalazine, Leflunomide, Methotrexate p.o., Methotrexate s.c., Etanercept, Adalimumab, Infliximab, Abatacept s.c., Abatacept i.v., Tablet, Coated tablet, , Solution for injection, Powder for concentrate for solution for infusion, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Solution for injection in dose-dispenser cartridge, Prolonged-release tablet, Xeljanz 5/10mg Filmtabletten, Otezla Filmtabletten, Simponi 50mg Injektionslösung Vorgefüllter Injektor/Fertigspritze, Cimzia 200mg Injektionslösung in einem Fertigpen, Orencia Injektionslösung in einer Fertigspritze, Orencia 250mg Pulver, Cosentyx 150mg Injektionslösung in einer Fertigspritze, Taltz, Cimzia 200mg Injektionslösung in einer Fertigspritze, Cimzia 200mg Injektionslösung in einer Patrone für ein Dosiergerät, Orencia 125mg Injektionslösung im Fertigpen, Cosentyx 150mg Injektionslösung in einem Fertigpen, Stelara 45mg/90mg Injektionslösung, Xeljanz 11mg Retardtablette, Rinvoq 15 mg Retardtablette, Tremfya 100mg Injektionslösung, Skyrizi 75/150mg Injektionslösung

Universitätsklinikum Erlangen, Universitätsklinikum Erlangen

Psoriatic arthritis Psoriasisarthritis, Psoriatic arthritis Gelenkbeteiligung bei Schuppenflechte, Diseases [C] - Immune System Diseases [C20]

2019-004246-15: Study to assess efficacy of secukinumab compared to ustekinumab in adult patients with psoriatic arthritis and previous TNFα-inhibitor treatment failure

Not yet recruiting

310

Europe

Secukinumab, Ustekinumab, AIN457, Solution for injection in pre-filled syringe, Cosentyx, Stelara

Novartis Pharma GmbH, Novartis Pharma GmbH

Psoriatic arthritis, Psoriatic arthritis, Diseases [C] - Musculoskeletal Diseases [C05]

2019-004652-11: A Study of Etrolizumab-Based Induction Therapy Combinations Followed by Etrolizumab Maintenance Therapy in Patients with Moderate-To-Severe Ulcerative Colitis

Ongoing

372

Europe

Etrolizumab, RO5490261/F04-02, Solution for injection in pre-filled syringe, Powder for concentrate for solution for infusion, Film-coated tablet, Concentrate for solution for infusion, Remicade, Xeljanz, Stelara

F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd

Ulcerative Colitis (UC), UC is a chronic disease of the large intestine, in which the lining of the colon becomes inflamed and develops tiny open sores, or ulcers, Diseases [C] - Digestive System Diseases [C06]

VESPUCCI, NCT04595409 / 2019-004364-21: A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis

Completed

392

Europe, RoW

FYB202 (Proposed ustekinumab biosimilar), Stelara® (Ustekinumab)

Bioeq GmbH, bioeq GmbH

Plaque Psoriasis

06/21

03/22

2021-000345-41: Extension of the RESCUE study to follow up on long term safety and efficacy of patients with Crohn's disease that received a dose escalation after the loss of response to ustekinumab Extension de l'étude RESCUE pour suivre la sécurité et l'efficacité à long terme des patients atteints de la maladie de Crohn qui ont reçu une augmentation de dose après la perte de réponse à l'ustekinumab. Uitbreiding van de RESCUE-studie met het oog op de follow-up van de veiligheid en doeltreffendheid op lange termijn van patiënten met de ziekte van Crohn die een dosisescalatie hebben gekregen na het verlies van respons op ustekinumab

Not yet recruiting

108

Europe

Solution for injection in pre-filled syringe, Stelara 90 mg solution for injection n pre-filled syringue

Belgian IBD research and development (BIRD vzw), Janssen Pharmaceutica NV

Crohn's disease ziekte van Crohn La maladie de Crohn, Chronic inflammatory bowel disease Chronische inflammatoire darmziekte La maladie inflammatoire chronique de l'intestin, Diseases [C] - Digestive System Diseases [C06]

2020-001045-39: Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patientswith Moderate to Severe Plaque Psoriasis

Not yet recruiting

446

Europe

Stelara, CT-P43, Solution for injection in pre-filled syringe, Solution for infusion in pre-filled syringe, Stelara

Celltrion, Inc, Celltrion, Inc.

Moderate to Severe Plaque Psoriasis, Moderate to Severe Plaque Psoriasis, Body processes [G] - Immune system processes [G12]

POWER, NCT03782376: A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease

Completed

215

Europe, US, RoW

Ustekinumab approximately 6 mg/kg (IV), STELARA, Placebo (SC), Placebo (IV), Ustekinumab 90 mg (SC) Group 1, Ustekinumab 90 mg (SC) Group 2

Janssen-Cilag Ltd.

Crohn Disease

08/22

01/23

NCT04728360 / 2020-004504-33: Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis

Completed

556

RoW

BAT2206, Stelara (EU-sourced)

Bio-Thera Solutions, Bio-Thera Solutions, Ltd.

Plaque Psoriasis

10/22

07/23

2020-005503-40: Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis Estudio para evaluar la eficacia, farmacocinética, seguridad e inmunogenicidad del ustekinumab o guselkumab administrado por vía subcutánea en participantes pediátricos con artritis psoriásica juvenil activa

Ongoing

Europe, RoW, US

Ustekinumab, Guselkumab, CNTO1275, CNTO1959, Solution for injection, Solution for injection in pre-filled syringe, STELARA®

Janssen-Cilag International NV, Janssen Research & Development, LLC

Juvenile Psoriatic Arthritis Artritis Psoriásica Juvenil, Juvenile Psoriatic Arthritis Artritis Psoriásica Juvenil, Diseases [C] - Skin and Connective Tissue Diseases [C17]

SOCRATES, NCT04089345: Stelara fOr ChRonic AntibioTic rEfractory pouchitiS

Completed

Europe

Ustekinumab, Stelara

Universitaire Ziekenhuizen KU Leuven, Janssen Pharmaceuticals

Pouchitis

12/22

05/23

2018-002629-51: A Clinical Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Chronic Inflammatory Bowel Disease That Affects the Lining of the Digestive Tract

Not yet recruiting

200

Europe, RoW

Ustekinumab, CNTO1275, Solution for injection in pre-filled syringe, Concentrate for solution for infusion, STELARA®

Janssen-Cilag International NV, Janssen-Cilag International N.V., JANSSEN CILAG INTERNATIONAL NV, Janssen Pharmaceutica NV, Janssen Pharmaceutica NV Belgium, Janssen-Cilag SpA

Crohn’s Disease, A chronic inflammatory bowel disease that affects the lining of the digestive tract, Diseases [C] - Immune System Diseases [C20]

STELLAR-2, NCT05335356: Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis

Completed

384

Stelara, Bmab1200

Biocon Biologics UK Ltd

Moderate to Severe Chronic Plaque Psoriasis

01/23

11/23

NCT04761627 / 2020-005205-42: A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Completed

494

Europe, Canada, US, RoW

Ustekinumab, Stelara®, ABP 654

Amgen

Psoriasis

02/23

ChiCTR2100045970: A Phase 3,Multicenter,Randomized,Double-blind study Evaluating the Efficacy and Safety of QX001S Compared with Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis

Recruiting

432

QX001S injection ;Ustekinumab injection

Peking University People's Hospital; Jiangsu Qyuns Therapeutics Co., Ltd., self-funded

Adult subjects with moderate to severe plaque psoriasis

NCT04882072: A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)

Terminated

Japan

Ustekinumab, Stelara®, CNTO1275, Placebo, Glucorticoid Taper Regimen

Janssen Pharmaceutical K.K.

Takayasu Arteritis

05/23

EMBRACE 1, NCT04305327 / 2019-001868-30: Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis

Terminated

Europe

Brodalumab, Kyntheum®, Ustekinumab, Stelara®, Placebo

LEO Pharma

Psoriasis

05/23

2020-004504-33: Study to Compare Efficacy and Safety of BAT2206 with Stelara® in Patients with Moderate to Severe Plaque Psoriasis

Not yet recruiting

556

Europe

Recombinant Human Anti-IL12 Monoclonal Antibody, BAT2206, Solution for injection in pre-filled syringe, Stelara®

Bio-Thera Solutions, Ltd., Bio-Thera Solutions, Ltd.

Moderate to Severe Plaque Psoriasis, chronic autoimmune disorder that causes the excessive buildup of skin cells, Diseases [C] - Skin and Connective Tissue Diseases [C17]

UKM-PS-III, NCT06488664: An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis

Active, not recruiting

422

RoW

GNR-068, ustekinumab biosimilar, Stelara®, ustekinumab

AO GENERIUM

Plaque Psoriasis

12/24

03/25

VIVID-1, NCT03926130 / 2018-004614-18: A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Feb 2022 - Feb 2022 : Data from P3 VIVID-1 trial for Crohn’s disease

Completed

1158

Europe, Canada, Japan, US, RoW

Mirikizumab, LY3074828, Ustekinumab, Placebo

Eli Lilly and Company

Crohn's Disease

08/23

10/23

2021-006668-25: Bmab 1200 versus Stelara® in Patients with Moderate to Severe Chronic Plaque Psoriasis

Not yet recruiting

384

Europe

Bmab 1200, STELARA 45 mg solution for injection in pre-filled syringe, Bmab 1200, Solution for injection in pre-filled syringe, STELARA 45 mg solution for injection in pre-filled syringe

Biocon Biologics UK Limited, Biocon Biologics UK Limited

Moderate to Severe Chronic Plaque Psoriasis, Plaque Psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17]

AgAIN, NCT04632927: Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment

Completed

119

Secukinumab, AIN457, Ustekinumab

Novartis Pharmaceuticals

Psoriatic Arthritis

10/24

NCT04505410: Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis

Completed

A plant based high fiber diet that mimics fasting ("FMD") plus advanced therapy, Advanced therapy only without dietary intervention

University of Miami, Pfizer

Ulcerative Colitis

12/23

BE TOGETHER, NCT06425549: A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

Recruiting

168

Europe, Canada, Japan, US, RoW

bimekizumab, BKZ, UCB4940, ustekinumab, USTE, placebo

UCB Biopharma SRL

Moderate to Severe Plaque Psoriasis

08/28

11/30

NCT06274554: Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease

Recruiting

120

Fluconazole, Diflucan, Placebo, IL-23 Therapy, Risankizumab, Ustekinumab

Weill Medical College of Cornell University, The Leona M. and Harry B. Helmsley Charitable Trust

Crohn's Disease, Inflammatory Bowel Diseases

12/28

12/29

OptIMMize-1, NCT04435600 / 2019-004141-32: A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

Completed

150

Europe, Canada, Japan, US

Risankizumab, SKYRIZI, ABBV-066, Ustekinumab

AbbVie

Psoriasis

02/24

10/24

NCT04610476: Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

Recruiting

270

Europe

Prednisolone, Prednisolone generic drugs, Sulfasalazine, Azulfidine, Leflunomide, Arava, Methotrexate, Lantarel, Metex, Tofacitinib, Xeljanz, Apremilast, Otezla, Etanercept, Enbrel, Erelzi, Benepali, Adalimumab, Humira, Amgevita, Imraldi, Hyrimoz, Infliximab, Remicade, Zessly, Inflectra, Certolizumab pegol, Cimzia, Golimumab, Simponi, Abatacept, Orencia, Secukinumab, Cosentyx, Ixekizumab, Taltz, Ustekinumab, Stelara

University of Erlangen-Nürnberg Medical School

Psoriatic Arthritis, Withdrawal, Reduction

10/24

10/25

REScUE, NCT04245215: Loss of RESponse to Ustekinumab Treated by Dose Escalation

Completed

108

Europe

Ustekinumab, dose escalation only in arm 2

Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW, Janssen Cilag N.V./S.A.

Crohn Disease

09/24

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall

Not yet recruiting

160

Europe

Illumetri, [ILUMETRI], Solution for injection in pre-filled syringe, Illumetri

Almirall S.A., Almirall SA, Almirall S.A., Almirall SA

2019-003218-15: A phase IV interventional study to assess the disease-modifying effect of long-term treatment with tildrakizumab in adult patients with moderate-to-severe plaque psoriasis

Not yet recruiting

Europe

Illumetri, Solution for injection in pre-filled syringe, Illumetri

Almirall S.A., Almirall S.A.

Moderate to severe plaque psoriasis, Moderate to severe plaque psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17]

2019-004230-42: Dose reduction of IL17 and IL23 inhibitors for psoriasis Dosis reductie van IL17 en IL23 remmers voor psoriasis

Not yet recruiting

244

Europe

secukinumab, ixekizumab, brodalumab, risankizumab, tildrakizumab, guselkumab, Injection, Cosentyx, Taltz, Kyntheum, Skyrizi, Ilumetri, Tremfya

Radboudumc, ZonMw, KCE

psoriasis psoriasis, psoriasis psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17]

ChiCTR2000033239: Study for the Efficacy and Safety of Tislelizumab (Anti-PD1 Antibody) Combined With chemotherapy

Not yet recruiting

China

Tislelizumab (Anti-PD1 Antibody) Combined With chemotherapy

Zhejiang Jinhua Guangfu Tumor Hospital ; None, Beigene

Non small cell lung cancer

Not yet recruiting

250

Europe

Illumetri, Skilarence, Solution for injection in pre-filled syringe, Gastro-resistant tablet, Illumetri, Skilarence

Almirall, Almirall

Moderate to severe chronic plaque psoriasis, Moderate to severe chronic plaque psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17]

NCT05110313: Effects of Tildrakizumab on Epigenetic Age

Completed

TILDRAKIZUMAB, ILUMYA™, tildrakizumab-asmn, ATC CODE: L04AC17 (WHO)

Carlos Wambier, Sun Pharmaceutical Industries Limited, Brown University, Lifespan, Ocean State Research Institute, Inc.

Psoriasis, Aging, Epigenetic Disorder, Inflammation; Skin

05/24

BeNeBio, NCT04340076: Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

Active, not recruiting

244

Europe

Secukinumab, Cosentyx, Ixekizumab, Taltz, Brodalumab, Kyntheum, Guselkumab, Tremfya, Risankizumab, Skyrizi, Tildrakizumab, Ilumetri, Bimekizumab, Bimzelx

Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Belgium Health Care Knowledge Centre, University Hospital, Ghent

Psoriasis, Psoriasis Vulgaris

12/25

BIOLOPTIM-TIL, NCT05683015: Therapeutic Drug Monitoring of Tildrakizumab in Psoriasis Patients

Recruiting

100

Europe

Venapuncture, Patient questionnaires

University Hospital, Ghent

Psoriasis Vulgaris

12/24

12/25

NCT04541329: Predicting Inflammatory Skin Disease Response to IL-23 Blockade

Completed

Tildrakizumab

University of California, San Francisco, Sun Pharmaceutical Industries Limited

Psoriasis Vulgaris

01/23

MINIMA, NCT04271540: MIcrovascular DysfuNction in Moderate-severe Psoriasis

Active, not recruiting

Tildrakizumab, Ilumya

Marcelo F. Di Carli, MD, FACC

Psoriasis, Cardiovascular Disease

07/24

06/25

NCT05390515: Psoriatic Immune Response to Tildrakizumab

Recruiting

Tildrakizumab Prefilled Syringe

University of California, San Francisco, Sun Pharmaceutical Industries Limited

Psoriasis Vulgaris

09/25

ChiCTR2400087931: Exploration of Precision Individualized Medication Regimen for Psoriasis

Not yet recruiting

278

Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, the National Key Research and Development Program of China (2023YFC2508103)

Not yet recruiting

472

Europe

Solution for injection, ILUMETRI

Sun Pharmaceutical industries Ltd, Sun Pharmaceutical Industries Ltd, Sun Pharma Global FZE, Sun Pharmaceutical industries Ltd, Sun Pharmaceutical Industries Ltd, Sun Pharma Global FZE

Active Psoriatic Arthritis, Diseases [C] - Skin and Connective Tissue Diseases [C17]

NCT05108766: A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis

Completed

220

RoW

Tildrakizumab 100 mg, SCH 90022, MK-3222, Placebo

Shenzhen Kangzhe Pharmaceutical Co., Ltd.

Plaque Psoriasis

06/21

07/22

Not yet recruiting

390

Europe

Solution for injection, ILUMETRI

Sun Pharmaceutical industries Ltd, Sun Pharmaceutical Industries Ltd, Sun Pharmaceutical industries Ltd, Sun Pharmaceutical Industries Ltd

Active Psoriatic Arthritis, Diseases [C] - Skin and Connective Tissue Diseases [C17]

NCT04314531: Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Active, not recruiting

296

Europe, Japan, US, RoW

TILD, matching placebo injections

Sun Pharmaceutical Industries Limited

Active Psoriatic Arthritis

06/25

11/25

NCT03897075: Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

Active, not recruiting

US, RoW

Tildrakizumab, Placebo

Sun Pharmaceutical Industries Limited

Chronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis

04/24

02/25

NCT04314544: Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Active, not recruiting

510

Europe, Canada, US, RoW

TILD, matching placebo injections

Sun Pharmaceutical Industries Limited

Active Psoriatic Arthritis

09/25

05/26

NCT06611163: A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

Not yet recruiting

192

Tildrakizumab 100 mg, Placebo

Sun Pharmaceutical Industries Limited

Moderate to Severe Genital Psoriasis

03/26

01/28

NCT04991116: Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

Recruiting

650

Europe, Canada, Japan, US, RoW

TILD sub-cutaneous (SC) injection

Sun Pharmaceutical Industries Limited

Psoriatic Arthritis

12/28

04/29

NCT03552276 / 2018-001060-35: Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

Completed

2/3

281

Europe, US, RoW

SUNPG18_07 I (Tildrakizumab 200 mg), SUNPG18_07 II (Tildrakizumab 100 mg)

Sun Pharmaceutical Industries Limited

Psoriatic Arthritis

09/23

NCT03997786 / 2019-003551-11: A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

Recruiting

2/3

130

Europe, US, RoW

Tildrakizumab, Placebo, Etanercept

Sun Pharmaceutical Industries Limited

Moderate-to-severe Chronic Plaque Psoriasis

07/25

12/31

ACTRN12620000984998: Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum 11 substudy 25-26: Tildrakizumab

Completed

The University of Sydney, Office for Health and Medical Research, Australian Genomic Cancer Medicine Centre (AGCMC)

Cancer, Advanced Osteosarcoma , Soft Tissue Sarcoma

2022-000706-10: Study on administration of Tildrakizumab in patients with Hidradenitis. Studie zur Anwendung von Tildrakizumab bei Patienten mit Akne.

Not yet recruiting

Europe

Solution for injection in pre-filled syringe, Ilumetri 100 mg Injektionslösung in einer Fertigspritze

University Medical Center of the Johannes Gutenberg- University Mainz, Almirall Hermal GmbH

Hidradenitis suppurativa Akne inversa, Hidradenitis Akne, Diseases [C] - Skin and Connective Tissue Diseases [C17]

ACTRN12623000211662: A Biomarker-Driven Approach to Identify Pathogenic Mechanisms and Novel Therapeutic Targets in Chronic Wounds (Pyoderma Gangrenosum) using Tildrakizumab

Completed

Liverpool Hospital, Sun Pharma

Pyoderma Gangrenosum

NCT04112810: Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease

Completed

Tildrakizumab, Iluyma

Medical College of Wisconsin

Hematologic Malignancies

06/24

2019-003485-40: ACTION: Abiraterone in Combination with Tildrakizumab

Not yet recruiting

1/2

Europe

YONSA, Ilumya, MK-3222, Tablet, Solution for infusion, YONSA, Ilumya

The Institute of Cancer Research

Metastatic castration resistant prostate cancer, Prostate cancer, Diseases [C] - Cancer [C04]

ACTIon, NCT04458311: Abiraterone Acetate in Combination With Tildrakizumab

Terminated

1/2

Europe

Abiraterone Acetate, Yonsa, Tildrakizumab

Institute of Cancer Research, United Kingdom, Sun Pharmaceutical Industries Limited

Metastatic Castration Resistant Prostate Cancer

04/23

11/23

NCT04465292: The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid

Not yet recruiting

Tildrakizumab Prefilled Syringe

Brigham and Women's Hospital, Joseph Merola

Pemphigoid, Bullous

12/22

05/23

TILDVIT-1227, NCT04971200: Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo

Completed

RoW

Tildrakizumab

Premier Specialists, Australia

Skin and Connective Tissue Diseases, Skin Diseases, Pigmentation Disorder, Hypopigmentation, Biologic, Vitiligo

11/24

SAIL, NCT04203693: Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice

Completed

N/A

331

Europe

Tildrakizumab

Almirall, S.A.

Plaque Psoriasis

04/24

NCT06488170: A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting

Recruiting

N/A

RoW

Tildrakizumab, IL-23p19 inhibitor

Almirall, S.A.

Plaque Psoriasis

01/25

ZODIPSO, NCT05938361: Efficacy of Tildrakizumab in Difficult-to-treat Areas in Psoriasis

Recruiting

N/A

120

Europe

Psoriasis clinical assessments, Quality of life evaluation, Satisfaction assessment, Pruritus evaluation

Clin4all

Psoriasis Palmaris, Psoriasis Genital, Psoriasis of Scalp, Psoriasis Plantaris, Psoriasis Nail

11/24

04/25

NCT03992729: Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab

Recruiting

N/A

200

Pregnant women exposed to tildrakizumab, Pregnant women not exposed to tildrakizumab

Sun Pharmaceutical Industries Limited

Pregnancy Related

12/25

POSITIVE, NCT04823247: Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - Study

Active, not recruiting

N/A

782

Europe

Tildrakizumab, IL-23p19 inhibitor

Almirall, S.A.

Plaque Psoriasis

01/25

NCT06030076: A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis

Recruiting

N/A

Europe

Tildrakizumab, Ilumetri®

Almirall, S.A.

Plaque Psoriasis

10/25

NCT06029257: A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)

Recruiting

N/A

110

Europe

Tildrakizumab, Ilumetri®

Almirall, S.A.

Genital Psoriasis

03/26

ACTRN12620001307998: A Prospective Photographic Analysis Of Psoriasis Severity Following Treatment With Tildrakizumab

Not yet recruiting

N/A

Samson Clinical Pty Ltd, Samson Clinical Pty Ltd

Psoriasis

ACTRN12609000233224: A Single-Dose Safety and Tolerability Placebo Controlled Study of Subcutaneous SCH 900222 in Healthy Volunteers

Recruiting

N/A

Schering-Plough, Schering-Plough

The use of SCH 900222 for autoimmune disorders.

Stelara (ustekinumab) / J&J

ACTRN12620000584932: CH-ALV-2001: A study assessing variations in how quickly STELARA is processed and cleared by the body, in healthy adult males.

Not yet recruiting

Christchurch Clinical Studies Trust, Christchurch Clinical Studies Trust

Psoriasis

2012-005809-53: What is the biologic drug concentration required to maintain stable disease activity in psoriasis?

Ongoing

Europe

adalimumab, etanercept, Ustekinumab, Solution for injection, Humira, Enbrel, Stelera

Psoriasis, Psoriasis, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]

Ongoing

Europe

Ustekinumab, Stelara, Stelara

University of Leeds/Leeds Teaching Hospitals NHS Trust, Leeds Foundation for Dermatology Research, Janssen-Cilag (Pharmaceuticals) Ltd.

Psoriatic disease (psoriasis and psoriatic arthritis).

2014-003148-11: Mechanism of action study of Ustekinumab treatment in psoriatic arthritis Studie naar het werkingsmechanisme van anti-Il17 therapie in spondyloartritis

Ongoing

Europe

ustekinumab, STELARA, STELARA

Academic Medical Center, Academic Medical Center

psoriatic arthritis artritis psoriatica

2015-000943-17: Dose decrease of biologics for psoriasis Dosis afbouwen van biologics voor psoriasis

Ongoing

120

Europe

Injection, Humira (adalimumab), Enbrel (etaneracept), Stelara (ustekinumab)

Radboudumc, Zonmw

Adult Patients diagnosed psoriasis vulgaris Volwassenen gediagnosticeerd met psoriasis vulgaris, Psoriasis Psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17]

2017-001695-26: Effectiveness and safety of biological drugs in psoriasis Efficacia e sicurezza dei farmaci biologici nella psoriasi

Not yet recruiting

154

Europe

ISTITUTI FISIOTERAPICI OSPITALIERI, AIFA - Italian Medicines Agency

2017-005151-83: Treatment of Crohn's disease with Ustekinumab in clinical practice

Ongoing

100

Europe

Stelara, Concentrate for solution for infusion, Solution for injection in pre-filled syringe, STELARA

Charité Universitätsmedizin Berlin, Janssen-Cilag GmbH

Crohn's disease, Crohn's disease, Diseases [C] - Digestive System Diseases [C06]

2018-002925-47: prediction of response to therapy in inflammatory bowel disease Predicción de respuesta al tratamiento en la enfermedad inflamatoria intestinal

Not yet recruiting

180

Europe

Injection, Infusion, Adalimumab, Infliximab, Golimumab, Ustekinumab, Vedolizumab

Fundación de Investigación Biomédica del Hospital Universitario de La Princesa, Instituto de Salud Carlos III

Inflammatory bowel disease Enfermedad inflamatoria intestinal, Corhn´s disease and ulcerative colitis Enfermedad de Crohn y colitis ulcerosa, Diseases [C] - Digestive System Diseases [C06]

Not yet recruiting

108

Europe

Solution for injection, Stelara 45 mg solution for injection

Belgian IBD research and development, Janssen Pharmaceutica NV

2019-001337-13: USTekinumab in fistulising Perianal Crohn’s Disease: The USTAP CD study

Not yet recruiting

146

Europe

Concentrate for solution for infusion, Solution for injection/infusion, STELARA, STELARA 90 mg solution for injection in pre-filled syringe

GETAID, JANSSEN

patient with moderate to severe Crohn’s diseasewith at least one active perianal fistula track, Crohn's diseasefistula perianal, Diseases [C] - Digestive System Diseases [C06]

2019-002038-35: A study meausring ustekinumab concentrations through dried blood spot sampling in Crohn’s disease patients

Not yet recruiting

Europe

Solution for injection in pre-filled syringe, Stelara

UZ Leuven, UZ Leuven, Department of Gastroenterology and Hepatology, KU Leuven, Laboratorium for Therapeutic and Diagnostic Antibodies

Crohn's disease, Crohn's disease, Diseases [C] - Digestive System Diseases [C06]

ChiCTR2000034861: Efficacy and safety of Ustekinumab in the treatment of Chinese patients with Crohn's disease: a multicenter, prospective, real-world clinical study

Recruiting

127

N/A

The First Affiliated Hospital of The Fourth Military Medical University (Xijing Hospital); Xijing Hospital, IBD group

Crohn's disease

NCT04996485: Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children

Recruiting

RoW

Secukinumab Injection, Ustekinumab Injection, Dupilumab Injection, Symptomatic therapy

National Medical Research Center for Children's Health, Russian Federation

Congenital Ichthyosis

03/23

06/23

NCT02144857: Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis

Recruiting

200

Europe

etanercept, Enbrel, ustekinumab, Stelara, cyclosporine, Neoral, Secukinumab, Cosentyx, Apremilast, Otezla

University of Athens

Psoriasis

09/23

12/23

BioIBD, NCT03885713: Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease

Completed

180

Europe

Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis

12/24

USTAP, NCT04496063: USTekinumab in Fistulising Perianal Crohn's Disease

Active, not recruiting

Europe

Ustekinumab, Stelara, Placebo

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, Janssen, LP

Crohn's Disease

06/25

12/25

NCT04629196: Induction Optimization With Stelara for Crohn's Disease

Terminated

Ustekinumab, Stelara

NYU Langone Health

Crohn Disease

01/24

Completed

150

None

Jiangsu Province Hospital; Jiangsu Province Hospital, sponsored by Herui

Crohn's disease

ChiCTR2200060604: Efficacy and safety of ustekinumab intravenous maintenance versus subcutaneous maintenance in Crohn's disease: a multicenter randomized controlled clinical trial

Recruiting

ustekinumab intravenous maintenance treatment ;ustekinumab subcutaneous maintenance treatment

Xijing Hospital, Air Force Military Medical University; Xijing Hospital, Air Force Military Medical University, National Natural Science Foundation of China, Nos.81772650

Crohn's disease

SIIT-CD, NCT05861167: SIIT Based on UST CDST in Patients With CD

Recruiting

140

RoW

selective intensive induction therapy based on ustekinumab clinical decision-making tools

Sixth Affiliated Hospital, Sun Yat-sen University

Crohn Disease

06/24

NCT06520397: Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease

Recruiting

214

RoW

Ustekinumab and Upadacitinib, Ustekinumab

Sixth Affiliated Hospital, Sun Yat-sen University

Crohn Disease

12/26

07/27

ChiCTR2300070321: Comparative effectiveness of infliximab optimization vs ustekinumab for secondary loss of response to infliximab in patients with moderate-to-severe Crohn’s disease

Not yet recruiting

N/A ;N/A

Crohn’s disease

NCT05270733: Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics

Recruiting

Ustekinumab, Guselkumab, Risankizumab

University Hospitals Cleveland Medical Center, LEO Foundation, Case Western Reserve University

Psoriasis

12/26

ChiCTR2200055424: Transabdominal ultrasound evaluation of transmural healing of ustekinumab in Chinese patients with active Crohn's disease: a multicenter prospective study

Recruiting

Ustekinumab therapy

Crohn's disease (CD)

NCT06788340: MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease

Not yet recruiting

166

Europe

PK-model to decide when to dose Vedolizumab and Ustekinumab

Odense University Hospital

Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis

03/27

NCT05029921: A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease

Active, not recruiting

182

RoW

Ustekinumab, STELARA

Janssen Research & Development, LLC

Crohn Disease

05/25

08/25

ChiCTR2300078772: Transmural healing evaluated by endoscopic ultrasound in patients with moderate to severe active Crohn's disease in China treated with ustekinumab: a prospective single-center study

Not yet recruiting

100

None

The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, None

Crohn's disease

Recruiting

212

Ustekinumab; Ustekinumab combined with enteral nutrition therapy

Shanghai Tenth People's Hospital; Shanghai Tenth People's Hospital, China foundation of Crohn's disease and Colitis

Crohn's disease

NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting

150

Canada, US

Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara

Takeda

Crohn's Disease

06/27

NCT05928039: PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease

Recruiting

297

Canada

University of Calgary, Alimentiv Inc.

Crohn Disease

07/27

12/28

SOPRANO-CD, NCT05169593: Prevention of Postoperative Endoscopic Recurrence with Endoscopy-driven Versus Systematic Biological Therapy

Recruiting

292

Europe

Biological Drug, Risankizumab, Vedolizumab, Ustekinumab, Infliximab, Adalimumab

Universitaire Ziekenhuizen KU Leuven

Crohn Disease

10/27

10/30

2020-004457-76: A Long-term Extension Study of Ustekinumab in Pediatric Participants with different medical conditions.

Ongoing

180

Europe

Ustekinumab, CNTO1275, Solution for injection, Solution for injection in pre-filled syringe, STELARA®

Janssen-Cilag International NV, Janssen Research & Development, LLC

2017-002012-13: n.a. n.a.

Not yet recruiting

Europe

IRCCS ISTITUTO CLINICO HUMANITAS, Ministero della Salute, Janssen-Cilag S.p.A.

Moderate to severe psoriasis. Psoriasi moderata severa., n.a. n.a., Diseases [C] - Skin and Connective Tissue Diseases [C17]

2019-003151-11: Stelara for Chronic AntibioTic refractory inflammation of the pouch: A Belgian multicenter study

Not yet recruiting

Europe

Stelara, Injection, ustekinumab (Stelara)

UZ Leuven, Janssen

Chronic antibiotic refractory and relapsing pouchitis, Chronic antibiotic refractory and relapsing inflammation of the pouch, Diseases [C] - Digestive System Diseases [C06]

Not yet recruiting

270

Europe

Universitätsklinikum Erlangen, Universitätsklinikum Erlangen

Psoriatic arthritis Psoriasisarthritis, Psoriatic arthritis Gelenkbeteiligung bei Schuppenflechte, Diseases [C] - Immune System Diseases [C20]

2019-004246-15: Study to assess efficacy of secukinumab compared to ustekinumab in adult patients with psoriatic arthritis and previous TNFα-inhibitor treatment failure

Not yet recruiting

310

Europe

Secukinumab, Ustekinumab, AIN457, Solution for injection in pre-filled syringe, Cosentyx, Stelara

Novartis Pharma GmbH, Novartis Pharma GmbH

Psoriatic arthritis, Psoriatic arthritis, Diseases [C] - Musculoskeletal Diseases [C05]

2019-004652-11: A Study of Etrolizumab-Based Induction Therapy Combinations Followed by Etrolizumab Maintenance Therapy in Patients with Moderate-To-Severe Ulcerative Colitis

Ongoing

372

Europe

F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd

Completed

392

Europe, RoW

FYB202 (Proposed ustekinumab biosimilar), Stelara® (Ustekinumab)

Bioeq GmbH, bioeq GmbH

Plaque Psoriasis

06/21

03/22

Not yet recruiting

108

Europe

Solution for injection in pre-filled syringe, Stelara 90 mg solution for injection n pre-filled syringue

Belgian IBD research and development (BIRD vzw), Janssen Pharmaceutica NV

2020-001045-39: Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patientswith Moderate to Severe Plaque Psoriasis

Not yet recruiting

446

Europe

Stelara, CT-P43, Solution for injection in pre-filled syringe, Solution for infusion in pre-filled syringe, Stelara

Celltrion, Inc, Celltrion, Inc.

Moderate to Severe Plaque Psoriasis, Moderate to Severe Plaque Psoriasis, Body processes [G] - Immune system processes [G12]

POWER, NCT03782376: A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease

Completed

215

Europe, US, RoW

Ustekinumab approximately 6 mg/kg (IV), STELARA, Placebo (SC), Placebo (IV), Ustekinumab 90 mg (SC) Group 1, Ustekinumab 90 mg (SC) Group 2

Janssen-Cilag Ltd.

Crohn Disease

08/22

01/23

NCT04728360 / 2020-004504-33: Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis

Completed

556

RoW

BAT2206, Stelara (EU-sourced)

Bio-Thera Solutions, Bio-Thera Solutions, Ltd.

Plaque Psoriasis

10/22

07/23

Ongoing

Europe, RoW, US

Ustekinumab, Guselkumab, CNTO1275, CNTO1959, Solution for injection, Solution for injection in pre-filled syringe, STELARA®

Janssen-Cilag International NV, Janssen Research & Development, LLC

Juvenile Psoriatic Arthritis Artritis Psoriásica Juvenil, Juvenile Psoriatic Arthritis Artritis Psoriásica Juvenil, Diseases [C] - Skin and Connective Tissue Diseases [C17]

SOCRATES, NCT04089345: Stelara fOr ChRonic AntibioTic rEfractory pouchitiS

Completed

Europe

Ustekinumab, Stelara

Universitaire Ziekenhuizen KU Leuven, Janssen Pharmaceuticals

Pouchitis

12/22

05/23

Not yet recruiting

200

Europe, RoW

Ustekinumab, CNTO1275, Solution for injection in pre-filled syringe, Concentrate for solution for infusion, STELARA®

Janssen-Cilag International NV, Janssen-Cilag International N.V., JANSSEN CILAG INTERNATIONAL NV, Janssen Pharmaceutica NV, Janssen Pharmaceutica NV Belgium, Janssen-Cilag SpA

Crohn’s Disease, A chronic inflammatory bowel disease that affects the lining of the digestive tract, Diseases [C] - Immune System Diseases [C20]

STELLAR-2, NCT05335356: Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis

Completed

384

Stelara, Bmab1200

Biocon Biologics UK Ltd

Moderate to Severe Chronic Plaque Psoriasis

01/23

11/23

NCT04761627 / 2020-005205-42: A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Completed

494

Europe, Canada, US, RoW

Ustekinumab, Stelara®, ABP 654

Amgen

Psoriasis

02/23

ChiCTR2100045970: A Phase 3,Multicenter,Randomized,Double-blind study Evaluating the Efficacy and Safety of QX001S Compared with Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis

Recruiting

432

QX001S injection ;Ustekinumab injection

Peking University People's Hospital; Jiangsu Qyuns Therapeutics Co., Ltd., self-funded

Adult subjects with moderate to severe plaque psoriasis

NCT04882072: A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)

Terminated

Japan

Ustekinumab, Stelara®, CNTO1275, Placebo, Glucorticoid Taper Regimen

Janssen Pharmaceutical K.K.

Takayasu Arteritis

05/23

EMBRACE 1, NCT04305327 / 2019-001868-30: Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis

Terminated

Europe

Brodalumab, Kyntheum®, Ustekinumab, Stelara®, Placebo

LEO Pharma

Psoriasis

05/23

2020-004504-33: Study to Compare Efficacy and Safety of BAT2206 with Stelara® in Patients with Moderate to Severe Plaque Psoriasis

Not yet recruiting

556

Europe

Recombinant Human Anti-IL12 Monoclonal Antibody, BAT2206, Solution for injection in pre-filled syringe, Stelara®

Bio-Thera Solutions, Ltd., Bio-Thera Solutions, Ltd.

Moderate to Severe Plaque Psoriasis, chronic autoimmune disorder that causes the excessive buildup of skin cells, Diseases [C] - Skin and Connective Tissue Diseases [C17]

UKM-PS-III, NCT06488664: An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis

Active, not recruiting

422

RoW

GNR-068, ustekinumab biosimilar, Stelara®, ustekinumab

AO GENERIUM

Plaque Psoriasis

12/24

03/25

VIVID-1, NCT03926130 / 2018-004614-18: A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Feb 2022 - Feb 2022 : Data from P3 VIVID-1 trial for Crohn’s disease

Completed

1158

Europe, Canada, Japan, US, RoW

Mirikizumab, LY3074828, Ustekinumab, Placebo

Eli Lilly and Company

Crohn's Disease

08/23

10/23

2021-006668-25: Bmab 1200 versus Stelara® in Patients with Moderate to Severe Chronic Plaque Psoriasis

Not yet recruiting

384

Europe

Bmab 1200, STELARA 45 mg solution for injection in pre-filled syringe, Bmab 1200, Solution for injection in pre-filled syringe, STELARA 45 mg solution for injection in pre-filled syringe

Biocon Biologics UK Limited, Biocon Biologics UK Limited

Moderate to Severe Chronic Plaque Psoriasis, Plaque Psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17]

AgAIN, NCT04632927: Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment

Completed

119

Secukinumab, AIN457, Ustekinumab

Novartis Pharmaceuticals

Psoriatic Arthritis

10/24

NCT04505410: Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis

Completed

A plant based high fiber diet that mimics fasting ("FMD") plus advanced therapy, Advanced therapy only without dietary intervention

University of Miami, Pfizer

Ulcerative Colitis

12/23

Recruiting

168

Europe, Canada, Japan, US, RoW

bimekizumab, BKZ, UCB4940, ustekinumab, USTE, placebo

UCB Biopharma SRL

Moderate to Severe Plaque Psoriasis

08/28

11/30

NCT06274554: Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease

Recruiting

120

Fluconazole, Diflucan, Placebo, IL-23 Therapy, Risankizumab, Ustekinumab

Weill Medical College of Cornell University, The Leona M. and Harry B. Helmsley Charitable Trust

Crohn's Disease, Inflammatory Bowel Diseases

12/28

12/29

OptIMMize-1, NCT04435600 / 2019-004141-32: A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

Completed

150

Europe, Canada, Japan, US

Risankizumab, SKYRIZI, ABBV-066, Ustekinumab

AbbVie

Psoriasis

02/24

10/24

NCT04610476: Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

Recruiting

270

Europe

University of Erlangen-Nürnberg Medical School

Psoriatic Arthritis, Withdrawal, Reduction

10/24

10/25

REScUE, NCT04245215: Loss of RESponse to Ustekinumab Treated by Dose Escalation

Completed

108

Europe

Ustekinumab, dose escalation only in arm 2

Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW, Janssen Cilag N.V./S.A.

Crohn Disease

09/24

12 3 »

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites